Search

Displaying results 4911 - 4920 of 10000 in total
  1. Drug

    Buformin

    go.drugbank.com/drugs/DB04830
    ApprovedWithdrawn

    It was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.

  2. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate. … ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract.

  3. Drug

    GSK-945237

    go.drugbank.com/drugs/DB15345
    Investigational

    and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.). … GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose

  4. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  5. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    in the activation pathway of the drug. … However, araC is only slowly converted to araCTP in the liver or in primary liver tumors due to low levels of an enzyme in the liver that is required for the conversion of araC to araCMP, the first step

  6. Drug

    rGLP-1

    go.drugbank.com/drugs/DB05433
    Experimental

    rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.

  7. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties. … FP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease).

  8. Drug

    Alipogene tiparvovec

    go.drugbank.com/drugs/DB13521
    Approved

    Alipogene tiparvovec is an adeno-associated viral vector of serotype 1-based gene therapy that delivers the Ser(447)X variant of the human lipoprotein lipase (LPL) gene. … It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.[A259796, A259801, A259806, A259811]

  9. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    Targeting IL-6 function can be achieved directly, or through interrupting the IL-6 receptor or gp130 receptor axes. … Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system.

  10. Drug

    Florantyrone

    go.drugbank.com/drugs/DB08975
    ApprovedWithdrawn

    Florantyrone is used in the treatment of biliary dyskinesia